Sonus, OncoGenex Merge Into Specialty Oncology Company

Combined company will have three drugs in clinical development, including lead candidate OGX-011 in Phase II for prostate cancer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet